{"filing":{"accession_number":"0001386570-26-000042","cik":"0001386570","ticker":"NAGE","company_name":"Niagen Bioscience, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"cdxc-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1386570/000138657026000042/cdxc-20260804.htm"},"events":[{"id":23947,"run_id":21659,"accession_number":"0001386570-26-000042","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Niagen Bioscience issued a press release announcing Q2 2026 earnings for the quarter ended June 30, 2026, reporting net sales of $29.8 million, net income of $1.0 million, and adjusted EBITDA of $3.0 million, along with operational highlights including new product launches and pharmaceutical program developments.","company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24310,"accession_number":"0001386570-26-000042","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 4, 2026. The Item 2.02 disclosure explicitly states \"Niagen Bioscience, Inc. (the 'Company') issued a press release announcing its earnings for the quarter ended June 30, 2026,\" with the full press release attached as Exhibit 99.1. The press release reports net sales of $29.8 million, net income of $1.0 million, and adjusted EBITDA of $3.0 million, along with operational highlights including new product launches and pharmaceutical program developments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:33:07.223477+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24311,"accession_number":"0001386570-26-000042","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure references a corporate presentation made available on the company's website, but the supplemental exhibit (EX-99.1) contains Niagen Bioscience's second quarter 2026 earnings release with detailed financial results including net sales of $29.8 million, net income of $1.0 million, and adjusted EBITDA of $3.0 million, along with operational highlights and 2026 outlook. This is a classic earnings release disclosure that would materially affect a reasonable investor's assessment of the registrant's financial performance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:33:07.223477+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24310,"accession_number":"0001386570-26-000042","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed on August 4, 2026. The Item 2.02 disclosure explicitly states \"Niagen Bioscience, Inc. (the 'Company') issued a press release announcing its earnings for the quarter ended June 30, 2026,\" with the full press release attached as Exhibit 99.1. The press release reports net sales of $29.8 million, net income of $1.0 million, and adjusted EBITDA of $3.0 million, along with operational highlights including new product launches and pharmaceutical program developments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:33:07.223477+00:00","company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","filing_date":"2026-08-04"},{"id":24311,"accession_number":"0001386570-26-000042","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure references a corporate presentation made available on the company's website, but the supplemental exhibit (EX-99.1) contains Niagen Bioscience's second quarter 2026 earnings release with detailed financial results including net sales of $29.8 million, net income of $1.0 million, and adjusted EBITDA of $3.0 million, along with operational highlights and 2026 outlook. This is a classic earnings release disclosure that would materially affect a reasonable investor's assessment of the registrant's financial performance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:33:07.223477+00:00","company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","filing_date":"2026-08-04"}]}